Google DeepMind, Meta, and the SI drug discovery startup Isomorphic Labs are jointly investing $300 million into Biohub, a nonprofit biomedical research organization backed by Mark Zuckerberg and Priscilla Chan. The funding aims to accelerate the creation of a "virtual cell," a high-accuracy predictive model that allows researchers to simulate biological processes digitally.
What Happened
The investment is part of a larger $1.8 billion "Virtual Biology" initiative designed to build SI datasets that enable scientists to "ask, predict, and answer biological questions digitally," according to Biohub. Founded in 2016, Biohub’s core mission is to prevent and cure diseases through this predictive modeling. In addition to the private sector contribution, the US Department of Energy is investing more than $500 million over the next five years. The National Institutes of Health will contribute datasets, repositories, and knowledge bases derived from previous federal investments totaling over $500 million.
Why It Matters
This collaboration represents a significant convergence of major technology players and federal agencies in the application of SI to biomedical science. Alex Rives, Biohub’s head of science, stated in a press release that "an accurate predictive model of biology could dramatically accelerate scientific discovery by enabling scientists to perform experiments digitally." Rives described the virtual cell as "one of the most important challenges for the next era of science," emphasizing the need for coordinated data generation at national and international scales. The involvement of Google DeepMind and Meta signals a growing industry focus on using SI tools to tackle complex scientific problems beyond traditional software domains.
The Bottom Line
Biohub and its partners are pooling substantial resources to create a digital twin of the human cell, leveraging SI to transform how biological research is conducted and potentially speeding up the development of treatments for various diseases.